Sandbox Reserved 1645
From Proteopedia
(Difference between revisions)
Line 5: | Line 5: | ||
== Structure == | == Structure == | ||
- | The protein fibrillin-1 contains 59 subunits either called '''epidermal growth factor-like domain''' ([[EGF]]), or '''transforming growth factor β binding protein-like domain''' (8 [[TGF-bp]]). EGFs are repeated in tandem along with the whole protein which represents about 75% of the total Fibrillin-1 length, and they are interrupted by the insertion of the TGF-bp units, which contain 8 cysteines each which form <scene name='86/868178/Disulfide_bridges_in_tgf-bp/2'>4 disulfide bridges</scene>. In total, there are 47 motifs of EGF in one Fibrillin-1, but only 43 of them contain calcium-binding sequences. In consequence, these EGF are named cb-EGF for their ability to bind calcium cations. Each EGF or cb-EGF unit contains 6 residues of cysteine which form <scene name='86/868178/Disulfide_bridges/1'>3 disulfide bridges</scene> (CYS1-CYS3, CYS2-CYS4, CYS5-CYS6) stabilizing the secondary structure of the protein. Cb-EGF units contain also a <scene name='86/868178/Ca_binding_site/1'>Ca2+ binding site</scene> composed especially of amino acids that contain an oxygen atom, or groups with an azote in their lateral chains (aspartic and glutamic acids, serine, asparagine and glutamine). These amino acids stabilize the calcium cation by interactions between positively charged cation and hetero-atoms (oxygen or azote) of the amino acid's lateral chain. Consequently, a pentagonal bipyramidal binding site is created in which one calcium cation is bound in every cb-EGF subunit of the fibrillin-1 protein. <ref>Sandra Schrenk Carola Cenzi Thomas Bertalot Maria Teresa Conconi Rosa Di Liddo, (2017), pages: 1213-1223,https://doi.org/10.3892/ijmm.2017.3343</ref> | ||
3D model represents these parts of fibrillin-1: <scene name='86/868178/Cbegf9/2'>cb-EGF9</scene>, <scene name='86/868178/Tb4/2'>TGF-bp 4 containing second hybrid domain</scene> and <scene name='86/868178/Cbegf10/1'>cb-EGF10</scene>. | 3D model represents these parts of fibrillin-1: <scene name='86/868178/Cbegf9/2'>cb-EGF9</scene>, <scene name='86/868178/Tb4/2'>TGF-bp 4 containing second hybrid domain</scene> and <scene name='86/868178/Cbegf10/1'>cb-EGF10</scene>. | ||
+ | |||
+ | The protein fibrillin-1 contains 59 subunits either called '''epidermal growth factor-like domain''' ([[EGF]]), or '''transforming growth factor β binding protein-like domain''' (8 [[TGF-bp]]). EGFs are repeated in tandem along with the whole protein which represents about 75% of the total Fibrillin-1 length, and they are interrupted by the insertion of the TGF-bp units, which contain 8 cysteines each which form <scene name='86/868178/Disulfide_bridges_in_tgf-bp/2'>4 disulfide bridges</scene>. In total, there are 47 motifs of EGF in one Fibrillin-1, but only 43 of them contain calcium-binding sequences. In consequence, these EGF are named cb-EGF for their ability to bind calcium cations. Each EGF or cb-EGF unit contains 6 residues of cysteine which form <scene name='86/868178/Disulfide_bridges/1'>3 disulfide bridges</scene> (CYS1-CYS3, CYS2-CYS4, CYS5-CYS6) stabilizing the secondary structure of the protein. Cb-EGF units contain also a <scene name='86/868178/Ca_binding_site/1'>Ca2+ binding site</scene> composed especially of amino acids that contain an oxygen atom, or groups with an azote in their lateral chains (aspartic and glutamic acids, serine, asparagine and glutamine). These amino acids stabilize the calcium cation by interactions between positively charged cation and hetero-atoms (oxygen or azote) of the amino acid's lateral chain. Consequently, a pentagonal bipyramidal binding site is created in which one calcium cation is bound in every cb-EGF subunit of the fibrillin-1 protein. <ref>Sandra Schrenk Carola Cenzi Thomas Bertalot Maria Teresa Conconi Rosa Di Liddo, (2017), pages: 1213-1223,https://doi.org/10.3892/ijmm.2017.3343</ref> | ||
== Biological Function == | == Biological Function == |
Revision as of 19:38, 14 February 2021
This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664. |
To get started:
More help: Help:Editing |
Fibrillin-1
|
References
- ↑ Handford, P. A. (2000). Fibrillin-1, a calcium binding protein of extracellular matrix. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1498(2), 84–90. https://doi.org/10.1016/S0167-4889(00)00085-9
- ↑ Sandra Schrenk Carola Cenzi Thomas Bertalot Maria Teresa Conconi Rosa Di Liddo, (2017), pages: 1213-1223,https://doi.org/10.3892/ijmm.2017.3343
- ↑ Robert N. Ono, Gerhard Sengle, Noe L. Charbonneau, Valerie Carlberg, Hans Peter Bächinger, Takako Sasaki, Sui Lee-Arteaga, Lior Zilberberg, Daniel B. Rifkin, Francesco Ramirez, Mon-LiChu, Lynn Y.Sakai. (2009). Latent Transforming Growth Factor β-binding Proteins and Fibulins Compete for Fibrillin-1 and Exhibit Exquisite Specificities in Binding Sites. Journal of Biological Chemistry, volume (284). https://www.sciencedirect.com/science/article/pii/S0021925818665056
- ↑ Shazia S. Chaudhry, Stuart A. Cain, Amanda Morgan, Sarah L. Dallas, C. Adrian Shuttleworth, Cay M. Kielty; Fibrillin-1 regulates the bioavailability of TGFβ1. J Cell Biol 29 January 2007; 176 (3): 355–367. doi: https://doi.org/10.1083/jcb.200608167
- ↑ Marfan Syndrome.https://www.omim.org/entry/154700?search=marfan%20syndrome&highlight=%28syndrome%7Csyndromic%29%20marfan
- ↑ E. Martínez-Quintana, F. Rodríguez-González, P. Garay-Sánchez, and A. Tugoresb. (2014).A Novel Fibrillin 1 Gene Mutation Leading to Marfan Syndrome with Minimal Cardiac Features. Molecular Syndormology, volume (5), 236-240.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188161/
- ↑ TGFBR2.https://www.omim.org/entry/190182?search=TGFBR2&highlight=tgfbr2
- ↑ Am J Hum Genet.(1999), Cysteine Substitutions in Epidermal Growth Factor–Like Domains of Fibrillin-1: Distinct Effects on Biochemical and Clinical Phenotypes, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288233/